Nanosphere, Inc. NSPH announced today that it will release early stage research data on potential cancer biomarkers requiring high sensitivity in an abstract for the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago from June 3 to 7, 2011.
The early data suggests that three of Nanosphere's ultra-sensitive protein assays demonstrate potential clinical relevance in bladder, kidney and prostate cancers. The assays were developed and run using the Verisens™ high-throughput research platform.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in